Mr. Speaker, I know the hon. member spoke about the impact on the pharmaceutical industry, the cost of drugs, or the investor-state provision. This is on the negative side. I would appreciate if she could highlight some of the positive items of CETA. In fairness to the discussion here, it would be nice if we could hear about the positive side of CETA from the hon. member.
In the House of Commons on February 6th, 2017. See this statement in context.